

Article

Efficacy, safety and immunogenicity of an *Escherichia coli*-produced bivalent human papillomavirus vaccine: An interim analysis of a randomized clinical trial

You-Lin Qiao, Ph.D., Ting Wu, Ph.D., Rong-Cheng Li, Yue-Mei Hu, B.Sc., Li-Hui Wei, M.D., Chang-Gui Li, Ph.D., Wen Chen, Ph.D., Shou-Jie Huang, M.Sc., Fang-Hui Zhao, Ph.D., Ming-Qiang Li, B.Sc., Qin-Jing Pan, M.D., Xun Zhang, M.D., Qing Li, M.D., Ying Hong, M.D., Chao Zhao, M.D., Wen-Hua Zhang, M.D., Yan-Ping Li, Kai Chu, B.Sc., Mei Li, M.D., Yun-Fei Jiang, M.D., Juan Li, M.Sc., Hui Zhao, Ph.D., Zhi-Jie Lin, B.Sc., Xue-Lian Cui, M.Sc., Wen-Yu Liu, B.Sc., Cai-Hong Li, M.Sc., Dong-Ping Guo, M.D., Li-Dong Ke, M.D., Xin Wu, M.Sc., Jie Tang, B.Sc., Guo-Qi Gao, M.D., Ba-Yi Li, B.Sc., Bin Zhao, Feng-Xian Zheng, Cui-Hong Dai, Meng Guo, M.Sc., Jun Zhao, M.Sc., Ying-Ying Su, Ph.D., Jun-Zhi Wang, M.D., Feng-Cai Zhu, M.Sc., Shao-Wei Li, Ph.D., Hui-Rong Pan, Ph.D., Yi-Min Li, M.D., Jun Zhang, M.Sc., and Ning-Shao Xia

Y.-L. Qiao, T. Wu, R.-C. Li, Y.-M. Hu, L.-H. Wei, C.-G. Li and W. Chen contributed equally to this article.

Author Affiliations: From National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing (Y.-L.Q., W.C., F.-H.Z., Q.-J.P., X.Z., and W.-H.Z.); the State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National

Institute of Diagnostics and Vaccine Development in Infectious Diseases,
Collaborative Innovation Center of Biologic Products, School of Public Health,
Xiamen University, Xiamen, Fujian (T.W., S.-J.H., M.G., J.Z., Y.-Y.S., S.-W.L., J.Z.,
and N.-S.X.), Guangxi Center for Disease Control and Prevention, Nanning, Guangxi
(R.-C.L. and Y.-P.L.); Jiangsu Provincial Center for Disease Control and Prevention,
Nanjing, Jiangsu (Y.-M.H., K.C., and F.-C.Z.); Peking University People's Hospital,
Beijing (L.-H.W. and C.Z.); National Institute for Food and Drug Control, Beijing
(C.-G.L., J.L., H.Z., and J.-Z.W.); Liuzhou Center for Disease Control and
Prevention, Liuzhou, Guangxi (M.-Q.L., X.-L.C., and X.W.); Shenzhen Maternity and
Child Healthcare Hospital, Shenzhen, Guangdong (Q.L.); the Affiliated Drum Tower
Hospital of Nanjing University Medical School, Nanjing, Jiangsu (Y.H., M.L., and
Y.-F.J.); Xiamen Innovax Biotech Company, Xiamen, Fujian (Z.-J.L., H.-R.P., and Y.-
M.L.); Funing Center for Disease Control and Prevention, Funing, Jiangsu (W.-Y.L.
and J.T.); Xinmi Maternal and Child Health Hospital, Xinmi, Henan (C.-H.L., G.-
Q.G., and F.-X.Z.); Yangcheng Maternal and Child Health Hospital, Yangcheng,
Shanxi (D.-P.G. and B.-Y.L.); and Fengning Hospital of Traditional Chinese
Medicine, Fengning, Hebei (L.-D.K., B.Z., and C.-H.D.)—all in China.

Address reprint requests to Prof. J. Zhang at the State Key Laboratory of Molecular
Vaccinology and Molecular Diagnostics, School of Public Health, Xiamen University,
Xiang'an South Rd., Xiamen 361102, China, or at zhangj@xmu.edu.cn; to Dr. Y.-L.
Qiao at 17 South Panjiayuan Lane, Beijing 100021, China, or at qiaoy@cicams.ac.cn;
or to Prof. N.-S. Xia at the National Institute of Diagnostics and Vaccine
Development in Infectious Diseases, School of Public Health, Xiamen University,
Xiang'an South Rd., Xiamen 361102, China, or at nsxia@xmu.edu.cn.

ABSTRACT

Background The high cost and insufficient supply of human papillomavirus (HPV) vaccines have slowed the pace of controlling cervical cancer. A phase 3 clinical trial was conducted to evaluate the efficacy, safety and immunogenicity of a novel *Escherichia coli*-produced bivalent HPV-16/18 vaccine.

Methods A multi-centre, randomized, double-blind trial started on November 22, 2012, in China. In total, 7372 eligible women aged 18-45 years were age-stratified and randomly assigned to receiving 3 doses of the test or control (hepatitis E) vaccine at months 0, 1 and 6. Co-primary endpoints included high-grade genital lesions and persistent infection (over 6 months) associated with HPV-16/18. The primary analysis was performed on a per-protocol susceptible population of individuals who were negative for relevant HPV type-specific neutralizing antibodies (at day 0) and DNA (at day 0 through month 7) and who received 3 doses of the vaccine. This report presents data from a pre-specified interim analysis used for regulatory submission.

Results In the per-protocol cohort, the efficacies against high-grade genital lesions and persistent infection were 100.0% (95% confidence interval [CI] = 55.6% to 100.0%, 0/3306 in the vaccine group vs. 10/3296 in the control group) and 97.8% (95% CI = 87.1% to 99.9%, 1/3240 vs. 45/3246), respectively. The side effects were mild. No vaccine-related serious adverse events were noted. Robust antibody responses for both types were induced and persisted for at least 42 months.

Conclusions The *Escherichia coli*-produced HPV-16/18 vaccine is well tolerated and highly efficacious against HPV-16/18 associated high-grade genital lesions and persistent infection in women.

Human papillomavirus (HPV) is the most common viral infection of the genital tract (1). Persistent infection with carcinogenic types may lead to precancerous lesions with the possibility of progressing to cancer (2). Globally, HPV types 16 and 18 are responsible for approximately 70% of cervical cancer cases (3). A large majority (>85%) of cervical cancer cases (445000 annually) occur in developing regions with limited resources, where cervical cancer accounts for ~12% of all cancers in women (4). Three highly efficacious HPV vaccines are currently commercialized and are listed in national immunization programmes in over 70 countries (4). These efforts have led to notable accomplishments, including a continuing reduction in the prevalence of HPV-16/18 and related precancerous lesions (5-7). Unfortunately, the high cost and insufficient supply of the current vaccines have greatly slowed the pace of their implementation in lower-income countries for the WHO call to action to eliminate cervical cancer (8, 9).

The currently marketed HPV vaccines, HPV-6/11/16/18 quadrivalent vaccine (10), HPV-6/11/16/18/31/33/45/52/58 9-valent vaccine (11) and HPV-16/18 bivalent vaccine (12), are all composed of L1 virus-like particles (VLPs) produced in eukaryotic cells as the immunogens. Notably, an *Escherichia coli* (*E. coli*)-produced bivalent HPV-16/18 L1 VLP vaccine candidate was shown to be safe and immunogenic in women (13, 14). The aim of the present phase 3 trial was to assess the efficacy, safety and immunogenicity of this HPV vaccine in women.

Methods

Study design and participants

This study is a multi-centre, randomized, double-blind, controlled (hepatitis E vaccine) clinical trial in adult women. Independent Ethics Committee approvals were

obtained, and the study was conducted in accordance with Good Clinical Practice.

Participants were recruited at 5 study sites in China. Women were eligible to participate in the study if they were healthy, nonpregnant, and aged 18-45 years (**Supplementary Table 1**). Written informed consent was obtained from all participants (ClinicalTrials.gov, NCT01735006). At each site, the participants were age-stratified (into two groups: 18-26 and 27-45 years) and randomly assigned (1:1) to receive either the HPV-16/18 vaccine or the control vaccine, which were identical in appearance, according to a permuted-block randomization list (with 12 codes per block) provided by an independent statistician.

The co-primary efficacy endpoints included the following: histopathologically confirmed HPV-16 and/or HPV-18 related grade 2 or higher cervical intraepithelial neoplasia (CIN), vulvar intraepithelial neoplasia (VIN) and/or vaginal intraepithelial neoplasia (VaIN) (the pathological endpoint); and persistent HPV-16 and/or HPV-18 infection (over 6 months, > 150 days) (the persistent infection endpoint).

Vaccines

The bivalent HPV test vaccine was a mixture of two aluminium hydroxide adjuvant-absorbed recombinant L1 VLPs of HPV-16 and HPV-18 expressed in *E. coli* (13-15). The vaccine formulation contained 40 µg of HPV-16 and 20 µg of HPV-18 L1 VLP, suspended in 0.5 mL of buffered saline and 208 µg of aluminium adjuvant. The control vaccine was a commercialized recombinant hepatitis E vaccine (HepE) (Xiamen Innovax, Xiamen, China) (16, 17).

Vaccination and follow-up visits

Three doses of the HPV vaccine or control vaccine were administered intramuscularly

at day 0, month 1 (28 to 60 days) and month 6 (150 to 240 days). All the participants were trained to record all adverse events (AEs) occurring within one month after each injection in diary cards. Throughout the trial, all serious adverse events (SAEs) and pregnancy outcomes were requested to be reported. Serum samples were collected at day 0 and at month 7 for all the participants. Clinical follow-up visits included a gynaecologic examination with collection of endocervical swab samples for Papanicolaou testing and HPV DNA testing. The visits were scheduled at day 0 and months 7, 12, 18, 24, 30, 42, 54 and 66 for all participants. At the time of the current interim analysis, data were available up to month 42.

Efficacy and immunogenicity endpoint assessments

Cytology, histopathology and HPV DNA testing were performed in a central laboratory at the Cancer Institute of the Chinese Academy of Medical Sciences (CICAMS). Cytology results were reported according to the Bethesda system-2001 (18, 19). Histopathological analysis was performed blindly by an independent pathology panel at CICAMS. Details of the colposcopy referral and biopsy algorithm were described in **Supplementary Figures 1**. The final judgements of endpoint events were made by the gynaecologist and the pathologist in the independent data and safety monitoring board (DSMB), who blindly reviewed the data for each case proposed by the principal investigator (**Supplementary Methods**).

HPV DNA testing was first performed using the HPV DNA enzyme immunoassay method (DEIA) (Labo Biomedical Products, Netherlands). Samples with positive or borderline (defined per the manual of the kit) findings were further typed by a reverse hybridization line probe assay (Labo Biomedical Products, Netherlands, based on licensed Innogenetics LiPA technology), and by HPV-16- and

HPV-18-specific polymerase chain reactions (HPV TS16/18, Labo Biomedical Products, Netherlands) (**Supplementary Figure 2**). Detection of the high-risk type of HPV in paraffin-embedded tissue specimens was considered to be associated with lesions. If more than one high-risk type of HPV was found in the paraffin section, causality was confirmed if the same HPV type was detected in the closest preceding exfoliated cell samples. Otherwise, all high-risk HPV types presenting in the lesion were considered to be associated with that lesion.

Immunogenicity was analysed in the per-protocol subset for immunogenicity (PPS-I), which included all participants who complied with the protocol, were negative for IgG antibody against the relevant types of HPV at entry, were negative for the relevant types of HPV DNA at day 0 through month 7, and had IgG antibody results at month 7. The immune persistence of the vaccine was assessed in a subcohort of PPS-I (PPS-P), containing participants from one selected study site who had IgG antibody data available at any of the follow-up visits after month 7. IgG antibodies against HPV-16 and HPV-18 at day 0 and month 7 were tested by an enzyme-linked immunosorbent assay (ELISA) using *E. coli*-expressed L1 VLPs of either type as coating antigens (20). The positive samples were further quantified using references traceable to the WHO international standards for antibodies against HPV-16 (NIBSC code 05/134) or HPV-18 (NIBSC code 10/140), expressed in international units (IU). The lower detection limits of the assays were 3.1 IU/mL for HPV-16 antibodies and 2.0 IU/mL for HPV-18 antibodies. For calculating the geometric mean concentration (GMC), antibody titres below the lower detection limit of the assay were given an arbitrary value of half the cutoff value. To determine the previous or prevalent infection at entry, neutralizing antibodies against HPV-16 or 18 on day 0 were tested using the pseudovirion-based neutralization assay (PBNA) (20, 21), which would

preserve the power of the study and avoid over-excluding participants from the per-protocol set (PPS) cohort.

Statistical analysis

The study was designed based on preventive efficacy against the pathological and persistent infection endpoints related to HPV-16 and/or -18 (HPV-16/18). Efficacy and confidence intervals (CIs) were calculated on the basis of the observed difference in event rates using accrued person time as the denominator. An exact conditional procedure was used to evaluate efficacy under the assumption that the numbers of cases with endpoint events in the vaccine and control groups were independent Poisson random variables (22).

Efficacy analyses were mainly based on the PPS (PPS-E for pathological endpoints and PPS-PI for persistent infection endpoints). The PPS cohort contained participants who: were susceptible to infection by a relevant type of HPV (susceptible participants, i.e., negative for the corresponding type of neutralizing antibody on day 0 and negative for the corresponding type of HPV DNA from day 0 through month 7); had received three doses of the test or control vaccine; had at least one effective endpoint follow-up visit after month 7; and had no severe protocol violation. To estimate vaccine efficacy in a population with less perfect compliance, a modified intention-to-treat analysis (mITT, mITT-E for pathological endpoint, and mITT-PI for persistent infection endpoint) was conducted on unrestricted susceptible participants who received at least one dose of the vaccine and were susceptible to infection by a relevant type of HPV. Case counting for the PPS and mITT analyses started from month 7. ITT analysis included those who received at least one dose, and baseline cases (at entry) were excluded.

The null hypotheses for the pathological endpoint and persistent infection, with an overall two-tailed alpha of 0.05, are that the lower limit of the 95% CI of efficacy is not higher than 0% and not higher than 25%, respectively. Two planned interim efficacy analyses were triggered on the basis of a fixed number of primary endpoint events detected in the PPS cohort. For the persistent infection endpoint, the interim efficacy analysis with a two-tailed alpha of 0.025 was triggered when at least 29 cases of persistent HPV-16/18 infection were identified. For the pathological endpoint, the calculated nominal alpha value was used to control the probability of type I error below 0.05 (two-tailed) based on the O'Brien-Fleming alpha dissipation function (23). The interim analysis with a two-tailed alpha value of 0.004 was performed when at least 9 CIN2+ cases associated with HPV-16/18 infection were detected.

To ensure adequate power for the interim analysis (a power of 80% with a two-sided alpha of 0.004) and the final analysis (a power of at least 90% with a two-sided alpha of 0.049) for a true vaccine efficacy of 85 to 90%, with an anticipated annual event rate of 0.2% for pathological endpoint, a total of 4327 per-protocol participants were required for the study. To compensate for dropouts, a total sample size of >6000 was needed.

When 10 CIN2+ cases related to HPV-16/18 were identified in the per-protocol cohort through the visits by February 28, 2017, an interim analysis was performed by the DSMB independently. Based on the positive suggestions given by the DSMB, interim analyses for licensing purposes were conducted, and the major findings are reported here.

Analyses for immunogenicity were performed in the PPS-P and PPS-I cohorts. Safety analyses were performed for all the participants who received at least one

injection.

Data from different sites involved in this trial were combined for analysis by using SAS software (version 9.1). All reported p values are two-sided with an alpha value of 0.05, except for those specifically indicated.

Results

In total, 8827 women attended the enrolment visit between November 22, 2012, and April 1, 2013. Of these women, 7372 met the eligibility requirements and were randomly assigned to receive the test vaccine (n = 3689) or the control vaccine (n = 3683) (**Figure 1**). 95.1% of women received all 3 doses of the assigned regimens (**Supplementary Table 2**). Baseline characteristics were similarly distributed between groups (**Table 1**). 81.4% and 89.4% of the participants were susceptible to HPV-16 and HPV-18 infections, respectively, i.e., negative for type-specific neutralizing antibody on day 0 and negative for the relevant type of HPV DNA from day 0 through month 7.

The participants were followed for an average of 3.3 years. In the PPS cohort for the pathological endpoint (PPS-E), which included 6602 of 7372 women who underwent randomization (89.6%), 10 women in total, all in the control group, developed high-grade genital lesions associated with HPV-16/18 (seven CIN2 cases and three CIN3 cases). The HPV vaccine prevented 100.0% (95% CI, 55.6 to 100.0, 0/3306 in the vaccine group vs. 10/3296 in the control group) of HPV-16/18 related high-grade genital lesions in this population. Furthermore, the vaccine provided an efficacy of 97.8% (95% CI, 87.1 to 99.9, 1/3240 vs. 45/3246) against persistent infection (over 6 months) associated with HPV-16/18 in the per-protocol cohorts (PPS-PI) (**Table 2**). The robustness of the vaccine efficacies against both co-primary

endpoints were further confirmed in the Kaplan-Meier plots (**Figure 2**). The percentage of women completing all three vaccinations was very high, so the per-protocol and mITT analyses are similar (**Table 2**).

Additionally, the vaccine statistically significantly lowered the risk of incident infection (**Table 2**) and cytological abnormalities of the cervix related to HPV-16/18 (**Supplementary Table 4**). For the non-vaccine types HPV-31/33/45, the vaccine decreased persistent infections related to these types as a combined group (47.2%, 95% CI, 0.0 to 73.1, **Table 3**), although this difference did not reach statistical significance ($P = 0.05$). The vaccine showed no effects on reducing genital lesions or clearing the prevalent infection for women with detectable HPV DNA for the vaccine types at baseline (**Supplementary Table 5**). Among those who received a single dose in the mITT cohort, only 1 persistent infection and 2 incident infection events related to HPV 16/18 occurred, and all of them were in the control group.

One month after the third dose of the HPV vaccine, all 2302 baseline seronegative women seroconverted for anti-HPV-16 (100.0%); the mean IgG antibody level (GMC) was 790.4 IU/mL (95% CI, 767.5 to 813.9), which was over 100 times higher than the mean antibody level acquired from natural infection (7.1 IU/mL, calculated from the antibody level at day 0 of 367 seropositive participants at entry). For HPV-18, the seroconversion rate was 99.9% (2799/2802), with a GMC of 267.9 IU/mL (95% CI, 260.4 to 275.6), which was over 50 times higher than the mean antibody level acquired from natural infection (4.7 IU/mL, the GMC of day 0 from 149 seropositive participants at entry). The vaccine-induced IgG antibodies decreased ~8 times (anti-HPV-16) or ~10 times (anti-HPV-18) during the first year after the third vaccination and then remained relatively stable to month 42 at levels of ~100 IU/mL (anti-HPV-16) and ~25 IU/mL (anti-HPV-18) (**Figure 3**).

Total AEs, local or systemic reactions, and unsolicited events occurred at similar rates between groups (**Table 4, Supplementary Table 6**). Pain at the injection site (34.0%) and fever ($>37.0\text{ }^{\circ}\text{C}$, 35.1%) were the most common reactions that occurred in the vaccine group. Most AEs were mild. The participants reporting SAEs were distributed similarly between groups, and none of the SAEs were considered to be related to vaccination (**Supplementary Table 7**).

Pregnancy was reported in 977 women from the vaccine group (26.5%) and 981 women from the control group (26.7%) (**Table 4**). The proportions of women who became pregnant and their outcome profiles were similar for both groups. No congenital anomalies or pregnancy complications/abnormal events were associated with the vaccination in either group.

Discussion

Similar to the marketed HPV vaccines (10, 12, 24, 25), the candidate *E. coli*-produced HPV-16/18 vaccine almost entirely prevented high-grade genital lesions and persistent infection associated with the vaccine types of HPV in susceptible women. The vaccine was well tolerated; no SAEs related to vaccination were noted. Furthermore, robust vaccine-induced antibody responses for both types were detected in almost all participants who received three doses of the vaccine.

The test vaccine demonstrated consistent high prevention efficacy against HPV-16/18 associated CIN2+ lesions, CIN1+ lesions and persistent infection in susceptible women. Additionally, the vaccine statistically significantly lowered the risk of incident infection as well as cytological abnormalities of the cervix related to HPV-16/18. Similar to the three licensed HPV vaccines, the test vaccine showed no

effect on reducing genital lesions or clearing the prevalent infections for women with detectable HPV DNA of the vaccine types at baseline (11, 26, 27).

Limited by the lower rate and longer time needed to induce high-grade lesions for HPV-18 than HPV-16 (28-30), the vaccine efficacy against the type-specific CIN2+ endpoint was confirmed for HPV-16 but not HPV-18 in this interim analysis. Nevertheless, the test vaccine demonstrates consistent high efficacy for preventing HPV-18 associated persistent infection, incident infection, and cytological abnormalities. Thus, the *E. coli*-produced HPV-16/18 vaccine is probably as effective at preventing high-grade lesions related to HPV-18 as it is at preventing high-grade lesions related to HPV-16.

The majority of the side effects of the test vaccine were mild. No SAEs were related to vaccination in either group. No meaningful clinical safety concerns regarding post-vaccination pregnancy or infant outcomes were raised. These findings confirm the well-tolerated profiles of HPV L1-VLP vaccines, which have been well-established for the available HPV vaccines (31).

The test HPV vaccine induced robust and durable antibody responses to both types in the vaccine. The seroconversion rates approached or equalled 100%. Peak IgG GMCs at one month after the third dose were over 100-fold (for HPV-16) and 50-fold (for HPV-18) higher than those induced by natural infection, then declined approximately 10-fold one year later and were stable over the next two years. The remaining antibody titres at month 42 were 15-fold or 5-fold higher than those after natural infection for type 16 or 18, respectively. A similar serological pattern was also noted for Gardasil (32). The priority target population for HPV vaccination is young adolescents, in which population a two-dose schedule was recommended. Immuno-

bridging data for the test HPV vaccine in girls are available, which are encouraging (33).

Our study is not without limitations. Although encouraging cross-protection effects on infection caused by some non-vaccine types of HPV were observed, the study did not have enough power due to the small number of cases, and more follow-up data are needed for the cross-protection analysis. Further studies such as head-to-head comparison studies with other HPV vaccines and bridging studies on girls of other races, would be valuable for future implementation of this vaccine.

As a robust protein expression host, *E. coli* has the characteristics of inexpensive culturing, high expression levels, short turnaround time and easy scale-up if the protein can correctly auto-folded (34). Hence, *E. coli* has been widely used in the biopharmaceutical industry for producing recombinant proteins for therapeutic use. However, the formation of specific conformational structures is essential for ensuring the efficacy of VLP-based vaccines, which is not easily achieved in many cases. To date, only one *E. coli*-expressed and VLP-based vaccine has been commercialized, which is well tolerated and high efficacious against hepatitis E (16, 17). It is estimated that millions of doses of the final HPV-16/18 VLP stock solution can be obtained from one 500-litre fermentation through the current manufacturing process.

In conclusion, the *E. coli*-produced bivalent HPV-16/18 vaccine is well tolerated and highly efficacious in preventing high-grade genital lesions and persistent infection associated with HPV-16/18. In addition to a potential new source of the cervical cancer preventive vaccine, the easy scale-up and low manufacturing cost of the *E. coli*-based manufacturing process is a promising improvement with regard to accessibility for resource-limited countries.

Funding

This work was supported by grants from the Chinese National High-tech R&D Program (863 program, 2012AA02A408), the Chinese National Major Scientific and Technological Special Project for “Significant New Drug Development” (2018ZX09308010 and 2012ZX09101316), the National Natural Science Foundation of China (81673240 and U1705283), the Fujian Provincial Major Scientific and Technological Project (2015YZ0002), the Chinese Academy of Medical Sciences Innovation Fund for Medical Sciences (CIFMS, 2017-I2M-B&R-03, and 2016-I2M-1-019) and Xiamen Innovax.

Notes

The study funder Xiamen Innovax prepared the test and control vaccines. The other funders had no role in the study design, data collection, data analysis, data interpretation, or writing of the report. Investigators from the HPV-003 Study Group collected data and cared for the study participants.

Conflicts of Interest: Y.-M.L., H.-R.P., Z.-J.L., M.G., X.-H.L., B.-Z.L., and H.-H.C. report being either current or former employees of Xiamen Innovax. No other potential conflicts of interest relevant to this article were reported.

Author Contributions: J.Z., Y.-L.Q., N.-S.X., T.W., R.-C.L., Y.-M.H., L.-H.W., C.-G.L., W.C. S.-J.H., F.-H.Z., J.-Z.W., F.-C.Z., S.-W.L., H.-R.P., and Y.-M.L. contributed to the study design, and J.Z., Y.-L.Q., T.W., S.-J.H., Y.-Y.S., and M.G. were the core team for data analysis and manuscript preparation. All the authors had access to a summary of all the trial data and had final responsibility for the decision to submit for publication.

Acknowledgements: We thank the below investigators for their contributions to this HPV-003 study (listed in alphabetical order): other investigators from the Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College: Bin Liu, Dao-Kuan Liu, Feng Chen, Hui-Fang Xu, Jian-Feng Cui, Li Zhang, and Yu-Qian Zhao; Liuzhou Maternity and Child Healthcare Hospital: Hong-Min Zhou and Hua Tao; Peking University People's Hospital: Jing-Ran Li, Ming-Zhu Li, Shu-Hui Cui, and Yun Zhao; Liuzhou Center for Disease Control and Prevention: Hai-Bo Wang and Xiao-Wei Wang; Funing Center for Disease Control and Prevention: Qing-Xia Dai, Shang-Bo Yang, Tian-Jie Yue, and Ya-Chun Gao; Xinmi Maternal and Child Health Hospital: Hong-Juan Li and Jin-Hong Liu; Yangcheng Maternal and Child Health Hospital: Yuan-Ping Ma; Fengning Hospital of Traditional Chinese Medicine: Xian-Qing Bi and Yang Zhai; other investigators from Xiamen University: Chun-Lan Zhuang, Fang-Fang Hu, Fei-Xue Wei, Huan Yu, Lin Wang, Ling-Xian Qiu, Qiao-Qiao Song, Sheng-Xiang Ge, Shu Chen, Si-Jie Zhuang, Wei Sheng, Wen-Gang He, Xiao-Hui Liu, Xiao-Ping Min, Xin-Jing Ma, Xiao-Juan Yu, Xing-Mei Yao, Xun Fang, Ya-Fei Li, Ya Zheng, Yue Huang, and Zhao-Feng Bi; Xiamen Innovax: Bi-Zhen Lin and Huan-Huan Cao; Data and Safety Monitoring Board: Jie-Lai Xia (chair), Ai-Qiang Xu, Li Geng, Li Zhu, and Si-Yan Zhan; and Statistical and Programming Support: Qiong Du.

References

1. Crosbie EJ, Einstein MH, Franceschi S, et al. Human papillomavirus and cervical cancer. *Lancet*. 2013;382(9895):889-899.
2. Schiffman M, Doorbar J, Wentzensen N, et al. Carcinogenic human papillomavirus infection. *Nat Rev Dis Primers*. 2016;2:16086.

3. de Martel C, Plummer M, Vignat J, et al. Worldwide burden of cancer attributable to HPV by site, country and HPV type. *Int J Cancer*. 2017;141(4):664-670.
4. Human papillomavirus vaccines: WHO position paper, May 2017. *Weekly Epidemiol Rec*. 2017,92(19):241-268.
5. Drolet M, B énard É, Boily M-C, et al. Population-level impact and herd effects following human papillomavirus vaccination programmes: a systematic review and meta-analysis. *Lancet Infect Dis*. 2015;15(5):565-580.
6. Garland SM, Kjaer SK, Munoz N, et al. Impact and Effectiveness of the Quadrivalent Human Papillomavirus Vaccine: A Systematic Review of 10 Years of Real-world Experience. *Clin Infect Dis*. 2016;63(4):519-527.
7. Benard VB, Castle PE, Jenison SA, et al. Population-Based Incidence Rates of Cervical Intraepithelial Neoplasia in the Human Papillomavirus Vaccine Era. *JAMA Oncol*. 2017;3(6):833-837.
8. The Global Alliance for Vaccines and Immunisation, HPV Supply and Procurement Roadmap. <https://www.gavi.org/library/gavi-documents/supply-procurement/hpv-supply-and-procurement--roadmap/>. Accessed Apr 4, 2019.
9. WHO Director-General calls for all countries to take action to help end the suffering caused. WHO: Sexual and reproductive health. <http://www.who.int/reproductivehealth/call-to-action-elimination-cervical-cancer/en/>. Accessed Apr 4, 2019.
10. The FUTURE II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. *N Engl J Med*. 2007;356(19):1915-1927.

11. Joura EA, Giuliano AR, Iversen OE, et al. A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women. *N Engl J Med.* 2015;372(8):711-723.
12. Paavonen J, Jenkins D, Bosch FX, et al. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. *Lancet.* 2007;369(9580):2161-2170.
13. Hu YM, Huang SJ, Chu K, et al. Safety of an Escherichia coli-expressed bivalent human papillomavirus (types 16 and 18) L1 virus-like particle vaccine: an open-label phase I clinical trial. *Hum Vaccin Immunother.* 2014;10(2):469-475.
14. Wu T, Hu YM, Li J, et al. Immunogenicity and safety of an E. coli-produced bivalent human papillomavirus (type 16 and 18) vaccine: A randomized controlled phase 2 clinical trial. *Vaccine.* 2015;33(32):3940-3946.
15. Gu Y, Wei M, Wang D, et al. Characterization of an Escherichia coli -derived human papillomavirus type 16 and 18 bivalent vaccine. *Vaccine.* 2017;35(35):4637-4645.
16. Zhu FC, Zhang J, Zhang XF, et al. Efficacy and safety of a recombinant hepatitis E vaccine in healthy adults: a large-scale, randomised, double-blind placebo-controlled, phase 3 trial. *Lancet.* 2010;376(9744):895-902.
17. Zhang J, Zhang XF, Huang SJ, et al. Long-Term Efficacy of a Hepatitis E Vaccine. *N Engl J Med.* 2015;372(10):914-922.
18. Solomon D, Davey D, Kurman R, et al. The 2001 Bethesda System: terminology for reporting results of cervical cytology. *JAMA.* 2002;287(16):2114-2119.

19. Wright TC, Cox JT, Massad LS, et al. 2001 consensus guidelines for the management of women with cervical cytological abnormalities. *JAMA*. 2002;287(16):2120-2129.
20. Zhao H, Lin ZJ, Huang SJ, et al. Correlation between ELISA and pseudovirion-based neutralisation assay for detecting antibodies against human papillomavirus acquired by natural infection or by vaccination. *Hum Vaccin Immunother*. 2014;10(3):740-746.
21. Pastrana DV, Buck CB, Pang YY, et al. Reactivity of human sera in a sensitive, high-throughput pseudovirus-based papillomavirus neutralization assay for HPV16 and HPV18. *Virology*. 2004;321(2):205-216.
22. Chan ISF, Bohidar NR. Exact power and sample size for vaccine efficacy studies. *Commun Stat - Theor M*. 1998;27(6):1305-1322.
23. O'Brien PC, Fleming TR. A multiple testing procedure for clinical trials. *Biometrics*. 1979;35(3):549-556
24. Ault KA, The FUTURE II Study Group. Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trials. *Lancet*. 2007;369(9576):1861-1868.
25. Skinner SR, Apter D, De Carvalho N, et al. Human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine for the prevention of cervical cancer and HPV-related diseases. *Expert Rev Vaccines*. 2016;15(3):367-387.
26. Hildesheim A, Herrero R, Wacholder S, et al. Effect of human papillomavirus 16/18 L1 viruslike particle vaccine among young women with preexisting infection - A randomized trial. *JAMA*. 2007;298(7):743-753.

27. Joura EA, Leodolter S, Hernandez-Avila M, et al. Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: a combined analysis of three randomised clinical trials. *Lancet*. 2007;369(9574):1693-1702.
28. Woodman CB, Collins S, Winter H, et al. Natural history of cervical human papillomavirus infection in young women: a longitudinal cohort study. *Lancet*. 2001;357(9271):1831-1836.
29. Moscicki AB, Schiffman M, Kjaer S, et al. Chapter 5: Updating the natural history of HPV and anogenital cancer. *Vaccine*. 2006;24 Suppl 3:S3/42-51.
30. Castellsague X. Natural history and epidemiology of HPV infection and cervical cancer. *Gynecol Oncol*. 2008;110(3 Suppl 2):S4-S7.
31. Global Advisory Committee on Vaccine Safety, 30 November - 1 December 2016. *Weekly Epidemiol Rec*. 2017;92(2):13-20.
32. Schiller JT, Castellsague X, Garland SM. A review of clinical trials of human papillomavirus prophylactic vaccines. *Vaccine*. 2012;30 Suppl 5:F123-F138.
33. Su YY, Hu YM, He WG, et al. Immunogenicity and safety of an E. coli-produced bivalent human papillomavirus (types 16 and 18) vaccine in girls aged 9 to 17 years: a randomized clinical trial. Paper reported at: The 32nd international papillomavirus conference; October 4, 2018; Sydney, Australia.
34. Huang X, Wang X, Zhang J, et al. Escherichia coli-derived virus-like particles in vaccine development. *Npj Vaccines*. 2017;2(1).

Tables

Table 1. Baseline Characteristics of the Participants

Characteristic	Vaccine group No. (%) (N=3689)	Control group No. (%) (N=3683)
General		
Mean age, y (SD)	30.0±7.40	29.9±7.33
Younger subgroup, age 18-26 y	1861 (50.4)	1862 (50.6)
Senior subgroup, age 27-45 y	1828 (49.6)	1821 (49.4)
Baseline HPV-associated findings		
HPV-16		
Detectable virus DNA from day 0 to month 7	141 (3.8)	138 (3.7)
Detectable neutralizing antibodies on day 0	467 (12.7)	459 (12.5)
Susceptible to infection*	2985 (80.9)	3013 (81.8)
HPV-18		
Detectable virus DNA from day 0 to month 7	53 (1.4)	60 (1.6)
Detectable neutralizing antibodies on day 0	186 (5.0)	180 (4.9)
Susceptible to infection*	3300 (89.5)	3292 (89.4)
Cytological findings at day 0		
Negative for intraepithelial lesion or malignancy (NILM)	3341 (90.6)	3354 (91.1)
Atypical squamous cells of undetermined significance (ASC-US)	195 (5.3)	192 (5.2)
Negative on Hybrid Capture-2 test	109 (3.0)	109 (3.0)
Positive on Hybrid Capture-2 test	86 (2.3)	83 (2.3)
Low-grade squamous intraepithelial lesion (LSIL)	108 (2.9)	96 (2.6)
High-grade squamous intraepithelial lesion (HSIL)	31 (0.8)	26 (0.7)
Atypical squamous cells cannot exclude high-grade lesion (ASC-H)	4 (0.1)	10 (0.3)
Adenocarcinoma in situ (AIS)	1 (0.03)	0 (0.0)
Atypical glandular cells (AGC)	7 (0.2)	2 (0.05)
Histopathological findings at day 0 [†]		
Cervical intraepithelial neoplasia grade 1 (CIN1)	40 (1.1)	44 (1.2)
Vaginal intraepithelial neoplasia grade 1 (VaIN1)	3 (0.08)	2 (0.05)
Cervical intraepithelial neoplasia grade 2 (CIN2)	29 (0.8)	32 (0.9)
Cervical intraepithelial neoplasia grade 3 (CIN3)	9 (0.2)	13 (0.4)
Microinvasive carcinoma (MIC)	0 (0.0)	1 (0.03)
Squamous cell carcinoma (SCC)	1 (0.03)	1 (0.03)

* Susceptible to infection by a relevant type of HPV, i.e., negative for type-specific

neutralizing antibodies on day 0 and negative for the relevant type of HPV DNA from day 0 to month 7. Missing data on neutralizing antibodies or DNA were not deemed negative.

† No cases of vaginal intraepithelial neoplasia grade 2 or higher (VaIN2+) or vulvar intraepithelial neoplasia (VIN) were diagnosed at entry.

Table 2. Vaccine efficacy against genital lesions, persistent infection, or incident infection associated with HPV-16 or HPV-18

Endpoint	Vaccine group				Control group				Vaccine efficacy, % (95% CI)	P‡
	Total participants	Person-years at risk*	No. of cases	Rate †	Total participants	Person-years at risk*	No. of cases	Rate †		
Lesion of the cervix, vagina, and vulva related to HPV-16/18§										
Participants in the per-protocol susceptible population (PPS-E)										
Lesion grade										
High grade (CIN2+/VIN2+/VaIN2+)	3306	9119.9	0	0	3296	9079.3	10	0.1	100.0 (55.6-100.0)¶	.002
Any grade (CIN1+/VIN1+/VaIN1+)	3306	9119.9	0	0	3296	9075.7	14	0.2	100.0 (70.0-100.0)	<.001
HPV type-specific high-grade lesion										
HPV-16	2885	7977.1	0	0	2911	8022.7	9	0.1	100.0 (49.0-100.0)	.004
HPV-18	3175	8765.7	0	0	3153	8694.4	1	0.01	100.0 (-3768.3-100.0)	1.00
Participants in the unrestricted susceptible population (mITT-E)										
Lesion grade										
High grade (CIN2+/VIN2+/VaIN2+)	3386	9304.1	0	0	3386	9291.1	10	0.1	100.0 (55.4-100.0)	.002
Any grade (CIN1+/VIN1+/VaIN1+)	3386	9304.1	0	0	3386	9287.5	14	0.2	100.0 (69.9-100.0)	<.001
HPV type-specific high-grade lesion										

HPV-16	2943	8110.8	0	0	2972	8165.6	9	0.1	100.0 (49.0-100.0)	.004
HPV-18	3252	8943.9	0	0	3239	8897.4	1	0.01	100.0 (-3779.7-100.0)	1.00
Persistent infection \geq 6-month duration										
Participants in the per-protocol susceptible population (PPS-PI)										
Related to HPV-16 or -18	3240	9026.5	1	0.01	3246	8904.9	45	0.5	97.8 (87.1-99.9)	<.001
Related to HPV-16	2833	7887.0	1	0.01	2863	7886.9	28	0.4	96.4 (78.4-99.9)	<.001
Related to HPV-18	3112	8687.7	0	0	3110	8595.7	19	0.2	100.0 (78.8-100.0)	<.001
Participants in the unrestricted susceptible population (mITT-PI)										
Related to HPV-16 or -18	3313	9219.9	1	0.01	3330	9113.4	48	0.5	97.9 (88.0-99.9)	<.001
Related to HPV-16	2884	8020.5	1	0.01	2920	8026.7	30	0.4	96.7 (79.9-99.9)	<.001
Related to HPV-18	3182	8872.6	0	0	3190	8797.2	20	0.2	100.0 (79.9-100.0)	<.001
Incident infection										
Participants in the per-protocol susceptible population (PPS-II)										
Related to HPV-16 or -18	3307	9059.1	44	0.5	3300	8952.0	144	1.6	69.8 (57.4-79.0)	<.001
Related to HPV-16	2886	7920.5	31	0.4	2914	7955.0	87	1.1	64.2 (45.5-77.1)	<.001
Related to HPV-18	3176	8729.6	14	0.2	3157	8628.8	66	0.8	79.0 (62.3-89.1)	<.001
Participants in the unrestricted susceptible population (mITT-II)										
Related to HPV-16 or -18	3388	9263.0	45	0.5	3391	9161.6	153	1.7	70.9 (59.2-79.6)	<.001
Related to HPV-16	2945	8064.6	32	0.4	2975	8096.4	91	1.1	64.7 (46.7-77.2)	<.001
Related to HPV-18	3253	8924.4	14	0.2	3244	8832.9	71	0.8	80.5 (65.1-89.8)	<.001

* Person-years at risk was defined as the cumulative follow-up years of the at-risk participants at the indicated time point. CI : confidence interval;

† The rate is the number of participants with the endpoint per 100 person-years at risk.

‡ Fisher's exact test was used to calculate the P values with two-sided test.

§ HPV-16/18 associated AIS and cervical cancer were defined as the high-grade lesion endpoint.

|| The 99.6% CI of the efficacy against HPV-16/18-related CIN2+/VIN2+/VaIN2+ in the PPS-E cohort is 14.2% to 100.0%.

Table 3. Vaccine cross-protection against carcinogenic HPV persistent infection (6 m) other than HPV-16/18 in the per-protocol cohort*

HPV type	Vaccine group				Control group				Vaccine efficacy % (95% CI)	P [§]
	No. of participants	No. of events	Person-years at risk [†]	Rate [‡]	No. of participants	No. of events	Person-years at risk [†]	Rate [‡]		
HPV-31	3278	8	9151.3	0.1	3280	13	9092.0	0.1	38.9 (-59.1-78.0)	0.38
HPV-33	3282	7	9159.7	0.1	3274	15	9072.3	0.2	53.8 (-20.4-84.1)	0.13
HPV-35	3289	8	9180.8	0.1	3286	15	9116.2	0.2	47.0 (-33.1-80.6)	0.21
HPV-39	3248	33	9011.2	0.4	3243	31	8952.0	0.3	-5.8 (-78.5-37.2)	0.90
HPV-45	3299	1	9228.3	0.01	3298	5	9167.4	0.1	80.1 (-77.6-99.6)	0.22
HPV-51	3225	41	8916.4	0.5	3218	28	8878.6	0.3	-45.8 (-144.8-12.0)	0.15
HPV-52	3075	67	8455.1	0.8	3108	52	8521.9	0.6	-29.9 (-90.3-10.9)	0.20
HPV-56	3257	31	9041.7	0.3	3266	29	9016.6	0.3	-6.6 (-83.3-37.8)	0.90
HPV-58	3258	23	9059.5	0.3	3248	28	8978.3	0.3	18.6 (-46.6-55.2)	0.58
HPV-59	3283	15	9157.8	0.2	3289	12	9125.8	0.1	-24.6 (-191.4-45.6)	0.70
HPV-66	3261	22	9065.8	0.2	3263	26	9024.0	0.3	15.8 (-54.6-54.5)	0.67
HPV-68	3257	25	9059.8	0.3	3257	20	9005.2	0.2	-24.2 (-135.9-33.7)	0.55
HPV-31/33/45	3314	16	9223.4	0.2	3312	30	9135.8	0.3	47.2 (0.0-73.1)	0.05

* Per-protocol cohort: included those who: were susceptible to infection by a relevant type of carcinogenic HPV other than HPV-16/18

(negative for the corresponding type of HPV DNA from day 0 through month 7); had received three doses of the test or control vaccine;

had an effective endpoint follow-up visit after month 7; and had no severe protocol violation.

[†] Person-years at risk was defined as the cumulative follow-up years of the at-risk participants at the indicated time point.

[‡] The rate is the number of cases per 100 person-years at risk.

[§] Fisher's exact test was used to calculate the P values with two-sided test.

Table 4. Safety outcomes*

Adverse Events	No. of adverse events (Rate, %)	
	Vaccine group	Control group
No. of participants who received ≥ 1 injection	3691 [†]	3681 [†]
Solicited local adverse events within 72 hours after each vaccination		
All local AEs	1396 (37.8)	1552 (42.2)
Local AEs \geq Grade 3	24 (0.7)	68 (1.8)
All pain	1256 (34.0)	1328 (36.1)
Pain \geq Grade 3	0 (0)	0 (0)
All induration	261 (7.1)	326 (8.9)
Induration \geq Grade 3	11 (0.3)	25 (0.7)
All red	162 (4.4)	244 (6.6)
Red \geq Grade 3	6 (0.2)	40 (1.1)
All swelling	160 (4.3)	282 (7.7)
Swelling \geq Grade 3	15 (0.4)	52 (1.4)
All pruritus	163 (4.4)	377 (10.2)
Pruritus \geq Grade 3	0 (0)	0 (0)
Solicited systemic adverse events within 72 hours after each vaccination		
All systemic AEs	1683 (45.6)	1701 (46.2)
Systemic AEs \geq Grade 3	8 (0.2)	5 (0.1)
All fever	1296 (35.1)	1253 (34.0)
Fever \geq Grade 3	7 (0.2)	4 (0.1)
All fatigue and weakness	275 (7.5)	282 (7.7)
Fatigue and weakness \geq Grade 3	0 (0)	1 (0.03)
All headache	259 (7.0)	274 (7.4)
Headache \geq Grade 3	0 (0)	0 (0)
All cough	189 (5.1)	217 (5.9)
Cough \geq Grade 3	0 (0)	0 (0)
All myalgia	122 (3.3)	164 (4.5)
Myalgia \geq Grade 3	0 (0)	0 (0)
All nausea	118 (3.2)	125 (3.4)
Nausea \geq Grade 3	0 (0)	0 (0)
All diarrhoea	102 (2.8)	104 (2.8)
Diarrhoea \geq Grade 3	1 (0.03)	0 (0)
All allergic reaction	40 (1.1)	62 (1.7)
Allergic reaction \geq Grade 3	0 (0)	0 (0)
All vomiting	36 (1.0)	44 (1.2)
Vomiting \geq Grade 3	0 (0)	0 (0)
Unsolicited events within 30 days after each vaccination [‡]		
All	1402 (38.0)	1380 (37.5)
\geq Grade 3	19 (0.5)	23 (0.6)
Serious adverse events during the entire study [§]		
Within 30 days after each vaccination		
All	21 (0.6)	22 (0.6)
Death	1(0.03)	0 (0)
During the entire study		

All	205(5.6)	244(6.6)
Death	3(0.08)	3(0.08)

Pregnancy and pregnancy outcomes during the entire study

Women becoming pregnant	977 (26.5)	981 (26.7)
No. of pregnancy events [†]	1187	1219
Ongoing	4 (0.3)	7 (0.6)
Normal delivery	554 (46.7)	613 (50.3)
Spontaneous abortion	68 (5.7)	68 (5.6)
Stillbirth	10 (0.8)	14 (1.1)
Maternal complications	11 (0.9)	7 (0.6)
Elective termination	540 (45.5)	510 (41.8)
No. of infants [#]	556	615
Normal infant	555 (99.8) [#]	613 (99.7) [#]
Congenital anomaly	0 (0)	2 (0.3) ^{**}
Other complications or abnormality	1 (0.2) ^{††}	0 (0)

* Symptoms with a frequency greater than 1% in any group are listed. Grade 3 pain

was defined as influencing daily activities or requiring multiple uses of narcotic analgesics. Grade 3 induration, redness, and swelling were defined as having a diameter of more than 30 mm or limiting daily activities. Grade 3 pruritus was defined as having systemic pruritus. Grade 1 fever was defined as a temperature of more than 37.0 °C, and grade 3 fever was defined as a temperature of more than 39.0 °C. Grade 3 fatigue and weakness were defined as normal activities being weakened >50% with a strong influence on daily activities in addition to the prevention of working. Grade 3 headache was defined as serious influence on daily activities, with response to the initial anaesthetic treatment. Grade 3 cough was defined as having a paroxysmal cough that could not be controlled via treatment. Grade 3 myalgia was defined as having severe muscular tenderness, with a strong influence on daily activities. Grade 3 nausea and vomiting were defined as having nausea or vomiting 6 times within 24 hours and no significant food intake, with intravenous infusion required. Grade 3 diarrhoea was defined as having watery stools > 6 times/day or bloody diarrhoea, orthostatic hypotension, electrolyte imbalance, and >2 L intravenous infusion. A grade 3 allergic reaction was defined as extensive urticaria and angioedema.

[†] By mistake, one participant in the vaccine group was given the control vaccine for dose 1, and two participants in the control group were given the test vaccine for dose 3. These three participants were classified into the vaccine group for safety analysis, according to the protocol.

[‡] Unsolicited adverse events included any adverse events that occurred during the period from day 8 to day 30 after each vaccination and any adverse events that occurred within 7 days after each vaccination but that had not been listed on the diary card for registering solicited adverse events. A grade 3 unsolicited event was defined as a severe and significant limitation of daily activities that required help in daily life, medical treatment or hospitalization.

[§] The data and safety monitoring board did not consider any of the serious adverse events, death or not, to be related to vaccination. All serious adverse events, categorized by organ system and treatment group, are provided in the **Supplementary Table 7**.

^{||} A total of 6 participants died during the entire study. Of them, one participant in the vaccine group committed suicide by consuming poison at 13 days post the first injection, and one participant with a history of type 2 diabetes (for >10 years) in the vaccine group died from diabetic ketoacidosis at 14 months post the third injection. The other 4 participants died from traffic accidents at 3 to 24 months after their last injections.

[¶] Some women became pregnant more than once.

[#] There were four twins, two in the vaccine group and two in the control group.

^{**} One woman who received three doses of the HepE vaccine was diagnosed with 7+2 weeks of pregnancy at 72 days after the last injection, and the foetus was found to have hydronephrosis. Her baby girl was born after the normal period of gestation by

Caesarean section, and the baby was then diagnosed with congenital ureter stenosis of the right kidney half a year later. Another baby boy born to a participant who received three doses of the HepE vaccine was diagnosed with heritable thalassemia. The data and safety monitoring board did not consider these events to be related to vaccination.

^{††} One participant became pregnant at 36 months after her third injection with the test HPV vaccine. At 28+6 weeks of pregnancy, due to a complication of severe pre-eclampsia, a male infant with a body weight of 1.4 kilograms was delivered by Caesarean section. The newborn improved and was discharged after receiving one week of medical care and treatment. The data and safety monitoring board did not consider this event to be related to vaccination.

Figure titles and legends

Figure 1. Study profile

* By mistake, one participant in the vaccine group was given the control vaccine (the commercialized recombinant hepatitis E vaccine containing 30 µg of recombinant hepatitis E virus capsid protein absorbed to aluminium adjuvant) for dose 1, and two participants in the control group were given the test vaccine for dose 3. According to the protocol, these participants were retained in the randomly assigned group for efficacy analysis but were classified into the vaccine group for safety analysis. † Susceptible to infection by a relevant type of HPV is defined as negative for the corresponding type of neutralizing antibody on day 0 and negative for the corresponding type of HPV DNA from day 0 through month 7. PPS-E, per-protocol set for the pathological endpoint. PPS-PI, per-protocol set for the persistent infection endpoint. PPS-I, per-protocol set for the immune endpoint. PPS-P, per-protocol set for the immune persistence endpoint.

Figure 2. Time until the development of high-grade genital lesions or persistent infection associated with HPV-16/18 in the susceptible population

Panel A shows the accumulation of cases with high-grade genital lesions related to HPV-16/18 in the per-protocol set (PPS-E). **Panel B** shows the accumulation of cases with persistent infection related to HPV-16/18 in the per-protocol set (PPS-PI). Error bars represent 95% confidence intervals. The bars for the vaccine group were artificially moved slightly to the left to allow better discrimination from those for the control group. Of note, due to the closing calendar date for this interim analysis, a small number of participants were at risk at months 42 and 48.

Figure 3. The persistence of vaccine-induced type-specific IgG antibodies in women who were administered three doses of the assigned vaccine or control regimens

The immune persistence of the vaccine was assessed in a subcohort containing susceptible participants who were seronegative for the relevant types of HPV at entry, who were DNA negative from day 0 to month 7, and who received three doses of the HPV vaccine or control HepE vaccine (PPS-P cohort). The positive samples were further quantified using references traceable to the WHO international standards for antibodies against HPV-16 (NIBSC code 05/134) or HPV-18 (NIBSC code 10/140), expressed in international units (IU). The lower detection limits of the eVLP-ELISAs were 3.1 IU/mL for HPV-16 antibodies and 2.0 IU/mL for HPV-18 antibodies. For calculating the geometric mean concentration (GMC) of the antibodies, antibody titres below the lower detection limit of the assay were given an arbitrary value of half the cutoff value. The bar showed the 95% confidence interval of the corresponding antibody level.